Meeting
2020 Genitourinary Cancers Symposium
Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.
Authors
Arielle G. Bensimon
Analysis Group, Inc., Boston, MA
Arielle G. Bensimon , Yichen Zhong , Umang Swami , Allison Briggs , Joshua Young , Yuan Feng , Yan Song , James Signorovitch , Oluwakayode Adejoro , Abhiroop Chakravarty , Mei Chen , Rodolfo F. Perini , Daniel M. Geynisman
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Translational Research
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 716)
Abstract #
716
Poster Bd #
H14
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Axitinib plus pembrolizumab in patients with advanced renal cell carcinoma: Long-term efficacy and safety from a phase Ib study.
First Author: Michael B. Atkins
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternative therapies in first-line (1L) advanced renal cell carcinoma (aRCC) by IMDC risk status: A network meta-analysis (NMA).
First Author: Pratik Rane
Poster
2024 ASCO Genitourinary Cancers Symposium
Pembrolizumab plus lenvatinib (P+L) versus alternate therapies in first-line (1L) for advanced renal cell carcinoma (aRCC): A network meta-analysis (NMA).
First Author: Kevin Yan
Poster
2024 ASCO Genitourinary Cancers Symposium
Network meta-analysis (NMA) to assess comparative efficacy of lenvatinib plus pembrolizumab compared with other first-line treatments for management of advanced renal cell carcinoma (aRCC).
First Author: Viktor Grünwald